

-continued

Gly	Pro	Trp	Cys	Tyr	Thr	Met	Asn	Pro	Arg	Iys	Leu	Phe	Asp	Tyr	Cys
65					70					75					80
Asp	Ile	Pro	Leu	Cys	Ala	Ser	Ser	Ser	Phe	Asp					
			85							90					

What is claimed is:

1. A method for determining the amount of Lp(a) in a sample comprising the steps of:

- (a) contacting said sample and an Lp(a) specific binding agent coupled to a solid support wherein said Lp(a) specific binding agent is a monoclonal antibody or fragment thereof that binds to substantially all Lp(a) via kringle 5 of apo(a), to plasminogen at less than 1% of Lp(a) binding and to LDL, VLDL, IDL and HDL at less than 2% of Lp(a) binding, for a time and under conditions to form binding agent-Lp(a) complexes; and
- (b) determining the amount of Lp(a) bound to said binding agent-Lp(a) complexes.

2. The method of claim 1 wherein said monoclonal antibody is selected from the group consisting of Mab Nos. 1-532-266, 1-390-191, 1-458-165, 1-892-230, 1-292-189, 1-431-378, 1-746-183, and 1-546-264.

3. The method of claim 1 wherein the solid support is selected from the group consisting of nitrocellulose, latex, nylon, polystyrene, beads, particles, magnetic particles, and glass fiber.

4. The method of claim 1 further comprising the step of separating said solid support from said sample before determining the amount of Lp(a) bound to said binding agent-Lp(a) complexes.

5. The method of claim 1 further comprising contacting an indicator reagent with said sample and said Lp(a) specific binding agent prior to step (b).

6. The method of claim 5 wherein said indicator reagent is selected from the group consisting of K4 specific monoclonal antibody, K4 polyclonal antibody, K4/K5 monoclonal antibody, K4/K5 polyclonal antibody and fragments of each.

7. The method of claim 5 further comprising the step of separating said solid support from said sample before determining the amount of Lp(a) bound to said binding agent-Lp(a) complexes.

8. The method of claim 5 wherein said Lp(a) specific binding agent is selected from the group consisting of Mab Nos. 1-532-266, 1-390-191, 1-458-165, 1-892-230, 1-292-189, 1-431-378, 1-746-183, and 1-546-264.

9. A method for determining the amount of Lp(a) in a sample comprising the steps of:

- (a) contacting said sample, an indicator reagent, and a capture reagent bound to a solid support wherein said indicator reagent is a labeled monoclonal antibody or fragment thereof that binds to substantially all Lp(a) via kringle 5 of apo(a), to plasminogen at less than 1% of Lp(a) binding and to LDL, VLDL, IDL and HDL at less than 2% of Lp(a) binding, for a time and under conditions to form capture reagent-Lp(a)-indicator reagent complexes; and
- (b) determining the amount of Lp(a) bound to said binding agent-Lp(a) complexes.

10. The method of claim 9 wherein said capture reagent is selected from the group consisting of K4 specific monoclonal antibody or a fragment thereof, K4 polyclonal antibody, K4 and K5 monoclonal antibody, K4 and K5 polyclonal antibody and fragments of each.

11. The method of claim 9 further comprising the step of separating said solid support from said sample before determining the amount of Lp(a) bound to said binding agent-Lp(a) complexes.

12. The method of claim 9 wherein said indicator reagent is selected from the group consisting of Mab Nos. 1-532-266, 1-390-191, 1-458-165, 1-892-230, 1-292-189, 1-431-378, 1-746-183, and 1-546-264.

13. A method for determining the amount of Lp(a) in a sample comprising the steps of:

- (a) contacting said sample, an Lp(a) specific binding agent wherein said Lp(a) specific binding agent is conjugated to a first charged substance, and an indicator reagent wherein said indicator reagent is monoclonal antibody or fragment thereof that specifically binds to kringle 5 of apo(a) for a time and under conditions to form binding agent-Lp(a)-indicator complexes;
- (c) contacting an insoluble solid phase material which is oppositely charged with respect to said first charged substance, such that said solid phase material attracts and attaches to said first charged substance; and
- (d) determining the amount of Lp(a) bound to said binding agent-Lp(a)-indicator complexes.

14. The method of claim 13 wherein said monoclonal antibody is selected from the group consisting of Mab Nos. 1-532-266, 1-390-191, 1-458-165, 1-892-230, 1-292-189, 1-431-378, 1-746-183, and 1-546-264.

15. The method of claim 13 wherein said first charged substance is an anionic or cationic monomer or polymer.

16. The method of claim 13 wherein said indicator reagent binds to substantially all Lp(a) via kringle 5 of apo(a), to plasminogen at less than 1% of Lp(a) binding and to LDL, VLDL, IDL and HDL at less than 2% of Lp(a) binding.

17. A method for determining the amount of Lp(a) in a sample comprising the steps of:

- (a) contacting said sample with an indicator reagent wherein said indicator reagent is a monoclonal antibody or fragment thereof that specifically binds to kringle 5 of apo(a) and with a solid support coated with Lp(a) for a time and under conditions to permit binding of said indicator reagent with said Lp(a) in said test sample and with said bound Lp(a); and
- (b) determining said amount of Lp(a) in said test sample by detecting the reduction in binding of said indicator reagent to said solid support as compared to the signal generated from a negative sample to indicate the presence of Lp(a) in said test sample.

18. The method of claim 17 wherein said monoclonal antibody binds to substantially all Lp(a) via kringle 5 of apo(a), to plasminogen at less than 1% of Lp(a) binding and to LDL, VLDL, IDL and HDL at less than 2% of Lp(a) binding.

19. The method of claim 17 wherein said monoclonal antibody is selected from the group consisting of Mab Nos. 1-532-266, 1-390-191, 1-458-165, 1-892-230, 1-292-189, 1-431-378, 1-746-183, and 1-546-264.

20. The method of claim 19 wherein at each occurrence therein, said labeled Lp(a) is replaced by labeled kringle 5 of apo(a).

39

21. The method of claim 17 wherein at each occurrence therein, said indicator reagent is replaced by labeled Lp(a) and said bound-Lp(a) is replaced by bound monoclonal antibody or a fragment thereof that specifically binds to kringle 5 of apo(a).

22. The method of claim 21 wherein said indicator reagent binds to substantially all Lp(a) via kringle 5 of apo(a), to plasminogen at less than 1% of Lp(a) binding and to LDL, VLDL, IDL and HDL at less than 2% of Lp(a) binding.

23. The method of claim 21 wherein said monoclonal antibody is selected from the group consisting of Mab Nos. 1-532-266, 1-390-191, 1-458-165, 1-892-230, 1-292-189, 1-431-378, 1-746-183, and 1-546-264.

24. A method for determining the amount of cholesterol associated with Lp(a) in a sample comprising:

- (a) contacting a sample and a monoclonal antibody or fragment thereof that binds to substantially all Lp(a) via

40

kringle 5 of apo(a), to plasminogen at less than 1% of Lp(a) binding and to LDL, VLDL, IDL and HDL at less than 2% of Lp(a) binding, wherein said antibody is coupled to a solid support;

- (b) separating said solid support from said sample; and
- (c) determining said amount of cholesterol bound to said solid support.

25. A test kit for the detection and quantification of lp(a) in a plasma sample, comprising a reagent which binds to substantially all Lp(a) via kringle 5 of apo(a), to plasminogen at less than 1% of Lp(a) binding and to LDL, VLDL, IDL and HDL at less than 2% of Lp(a) binding.

26. The test kit of claim 25 wherein said reagent is labeled.

\* \* \* \* \*